Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Luca Gravina

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
Current Cancer Drug Targets|March 22, 2017
Editorial: New Therapeutic Approaches for the Treatment of GlioblastomaClaudio Festuccia, Giovanni Luca Gravina
Anti-Cancer Agents in Medicinal Chemistry|September 10, 2015
Editorial: Antitarget Therapies: New Frontiers in the Treatment of CancerClaudio Festuccia, Alessio Lodola, Giovanni Luca Gravina
Current Drug Targets|February 16, 2016
Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate CancerClaudio Festuccia, Paola Negri-Cesi, Giovanni Luca Gravina
Biomed Research International|September 13, 2014
Advances in prostate cancer research and treatmentLorenzo Livi, Andrea M Isidori, David Sherris, et al.
Current Cancer Drug Targets|August 17, 2016
New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point InhibitorsFrancesca De Felice, Daniela Musio, Raffaele Cassese, et al.
Oncotarget|August 25, 2016
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic resultsFrancesca De Felice, Daniela Musio, Giovanni Luca Gravina, et al.
Journal of Hematology & Oncology|December 6, 2014
Nucleo-cytoplasmic transport as a therapeutic target of cancerGiovanni Luca Gravina, William Senapedis, Dilara McCauley, et al.
Journal of Cancer Research and Clinical Oncology|April 25, 2003
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary culturesCarlo Vicentini, Claudio Festuccia, Giovanni Luca Gravina, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2005
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cellsClaudio Festuccia, Adriano Angelucci, Giovanni Luca Gravina, et al.
International Journal of Cancer|February 9, 2005
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitroClaudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, et al.
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
Current Cancer Drug Targets|March 22, 2017
Editorial: New Therapeutic Approaches for the Treatment of GlioblastomaClaudio Festuccia, Giovanni Luca Gravina
Anti-Cancer Agents in Medicinal Chemistry|September 10, 2015
Editorial: Antitarget Therapies: New Frontiers in the Treatment of CancerClaudio Festuccia, Alessio Lodola, Giovanni Luca Gravina
Current Drug Targets|February 16, 2016
Editorial: New Drug Targets for Treatment of Recurrent/Metastatic Prostate CancerClaudio Festuccia, Paola Negri-Cesi, Giovanni Luca Gravina
Biomed Research International|September 13, 2014
Advances in prostate cancer research and treatmentLorenzo Livi, Andrea M Isidori, David Sherris, et al.
Current Cancer Drug Targets|August 17, 2016
New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point InhibitorsFrancesca De Felice, Daniela Musio, Raffaele Cassese, et al.
Oncotarget|August 25, 2016
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic resultsFrancesca De Felice, Daniela Musio, Giovanni Luca Gravina, et al.
Journal of Hematology & Oncology|December 6, 2014
Nucleo-cytoplasmic transport as a therapeutic target of cancerGiovanni Luca Gravina, William Senapedis, Dilara McCauley, et al.
Journal of Cancer Research and Clinical Oncology|April 25, 2003
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary culturesCarlo Vicentini, Claudio Festuccia, Giovanni Luca Gravina, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2005
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cellsClaudio Festuccia, Adriano Angelucci, Giovanni Luca Gravina, et al.
International Journal of Cancer|February 9, 2005
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitroClaudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, et al.
Pageof 16